Wall Street Zen Upgrades Strata Skin Sciences (NASDAQ:SSKN) to Sell

Strata Skin Sciences (NASDAQ:SSKN) was upgraded by stock analysts at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Strata Skin Sciences in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Strata Skin Sciences currently has a consensus rating of “Hold” and a consensus target price of $6.00.

Strata Skin Sciences Stock Down 9.1%

SSKN stock opened at $1.89 on Friday. Strata Skin Sciences has a one year low of $1.38 and a one year high of $3.86. The firm has a market cap of $7.88 million, a PE ratio of -0.67 and a beta of 0.50. The firm’s 50 day moving average price is $1.88 and its 200-day moving average price is $2.22. The company has a debt-to-equity ratio of 49.58, a quick ratio of 0.75 and a current ratio of 0.98.

Strata Skin Sciences (NASDAQ:SSKN) last issued its quarterly earnings data on Wednesday, August 13th. The medical device company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.33). Strata Skin Sciences had a negative return on equity of 266.94% and a negative net margin of 35.13%.The business had revenue of $7.70 million during the quarter, compared to analysts’ expectations of $8.56 million. On average, equities research analysts anticipate that Strata Skin Sciences will post -1.05 EPS for the current year.

About Strata Skin Sciences

STRATA Skin Sciences, Inc, a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment.